Trillium Asset Management LLC Lowers Stock Position in Thermo Fisher Scientific Inc. $TMO

Trillium Asset Management LLC cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,939 shares of the medical research company’s stock after selling 2,881 shares during the period. Trillium Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $19,874,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in TMO. Brighton Jones LLC raised its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. Darwin Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the second quarter worth $170,000. Raymond James Financial Inc. raised its position in Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after acquiring an additional 53,542 shares during the period. Finally, California State Teachers Retirement System raised its position in Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after acquiring an additional 2,262 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $468.80 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The firm has a market capitalization of $174.22 billion, a price-to-earnings ratio of 25.77, a PEG ratio of 2.11 and a beta of 0.88. The company has a fifty day simple moving average of $479.14 and a 200-day simple moving average of $527.68. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the prior year, the firm earned $5.15 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

TMO has been the subject of a number of research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective for the company. Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Finally, Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a report on Thursday. They set a “neutral” rating and a $510.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $608.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.